Influenza (seasonal)

Development Of Universal Flu Vaccine Is On The Horizon

With the new type of antibodies capable of counteracting different strains of influenza A viruses, universal flu vaccines may be developed.  Based on a new research at McMaster University and the Icahn School of Medicine at Mount Sinai, New York, this vaccine is different from the current seasonal vaccines that are frequently reformulated because of high mutation rates of flu viruses.  People just need to take a single annual shot of this new vaccine to protect themselves from all serotypes of flu viruses, including the strains that undergo constant mutation.  

La grippe particulièrement sévère cette année

Une forte activité de la grippe saisonnière est enregistrée en ce mois de janvier avec des cas de décès dans certaines localités. Parmi ces victimes figurent des enfants, une femme enceinte et des personnes âgées, soit les personnes à risque de complication et pour lesquelles la vaccination contre la grippe est recommandée.

Study: Boosted flu vaccine benefits elderly in care facilities

A study published Thursday finds that the Fluzone High-Dose vaccine, which contains four times more antigens than the regular vaccine, benefits elderly recipients who live in long-term care facilities.
The University of Pittsburgh School of Medicine recently completed the first study of high-dose vaccines for elderly in care facilities.

Study finds flu virus, vaccine effect closely tied

A Swiss study released Thursday said how much protection the flu shot provides depends on how closely the vaccine matches the circulating virus.
Adrian Egli and colleagues from the University of Basel began with blood samples from organ-transplant patients, as these individuals are at an increased risk for acquiring infections because their immune systems are riddled by immune-suppressive drugs used to prevent rejection. Under these circumstances, vaccines fail to work well.

Flu vaccines increase immunity against multiple viruses

Researchers at St. Jude Children’s Research Hospital recently found that seasonal flu vaccines may boost immune systems against multiple flu viruses and not just the viruses in the vaccine.
Scientists at the hospital tested the immune responses of study participants who had received their flu vaccines and found that the participants had a strong immune response against many different types of flu, including the H3N2 flu strain from 2010.

University of Buffalo Develops new transport System for DNA Vaccines for HIV, Malaria, HPV, and Other Major Illnesses

Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies.
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

CDC's flu warning raises questions about vaccine match

The Centers for Disease Control and Prevention (CDC) warned yesterday that the profile of influenza viruses currently circulating, with A/H3N2 predominant, suggests a risk for a rough ride this winter, especially since about half of the H3N2 viruses don't match up with the corresponding strain in this year's vaccine.

STC to work with Alberta Health to control vaccine inventory

Scientific Technologies Corporation (STC) was recently awarded a contract with Alberta Health to help improve the management process and distribution of vaccine supply.

Hybrid Delivery System Boosts DNA Vaccines Potential

Scientists from the University at Buffalo have created a novel hybrid system designed to deliver genetic antigens and elicit a strong immune response in patients, something DNA vaccines have so far failed to deliver. The hybrid, presented in the Proceedings of the National Academy of Science and described as a “hybrid biosynthetic gene therapy vector development and dual engineering capacity,” brings together two usually distinct technologies to create a hybrid vector: combining a bacterial cell and a synthetic polymer.


Authorities Deem Novartis’ FLUAD Safe

Towards the end of November Italian officials prohibited the use of two batches of Novartis’ flu vaccine FLUAD after 13 deaths were reported to have taken place shortly after vaccination (8 within 24 hours). There were concerns from the AIFA that there may have been quality deficits within the two batches affected (143 301 and 142 701), however they and the ISS have deemed the vaccine safe after a series of negative results from preliminary tests.